MACROGENICS, INC. Deferred Revenue Recognized
MACROGENICS, INC. (MGNX) reported Deferred Revenue Recognized of $9.59 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-02-25.
Discontinued › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2020-02-25
- MACROGENICS, INC. contract with customer, liability, revenue recognized for the quarter ending 2018-03-31 was $1.94M.
- MACROGENICS, INC. contract with customer, liability, revenue recognized for fiscal 2018 was $9.59M.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2018-12-31 | $9.59M 10-K · filed 2020-02-25 | |||
| 2018-09-30 | $6.31M 10-Q · filed 2018-11-07 | |||
| 2018-06-30 | $3.87M 10-Q · filed 2018-08-07 | |||
| 2018-03-31 | $1.94M 10-Q · filed 2018-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |